1.DETERMINATION OF MULTIPLE DIAGNOSTIC INDICES IN LUNG CANCER
Medical Journal of Chinese People's Liberation Army 1981;0(06):-
In 161 cases of the lung cancer, serum values of CEA. CIC. ACE. CRP. IgE and ferritin were determined. It was found that their serum CEA. CIC. CRP and ferritin were higher, whereas serum ACE was lower than that of normal healthy subjeots and those suffering from benign pulmonary diseases. Serum CEA and CIC were distinctly lowered following surgical resection, radioor chemotherapy while the serum ACE activity was slightly elevated. Simultaneous determination of ferritin and CEA might increase the chance for detection of the lung cancer. The results of the study showed that determination of multiple indices are helpfui in the diagnosis, evaluation of the therapeutic response detection of relapse and prognosis of the lung cancer.
2.Clinical trial of biochemotherapy versus chemotherapy or biotherapy for malignant melanoma
Nan DU ; Liushu LI ; Wenhua XIAO
Medical Journal of Chinese People's Liberation Army 1982;0(03):-
Objective To compare the short-term and long-term efficacy of chemotherapy with biotherapy and same chemotherapy followed by biotherapy on malignant melanoma in stage Ⅲ and Ⅳ.Methods 82 cases with malignant melanoma were treated with chemotherapy(dacarbazing,cis-platin and carmustine)or biotherapy(interleukin-2,interferon ? and dendritic cell vaccine)or biochemotherapy(chemotherapy plus biotherapy).Among them,32 cases were received biochemotherapy,26 for biotherapy and 24 for chemotherapy.Therapentic response was assessed every 3 cycles.The median time of follow up was 2 years(1-4 years).Results Response rate was 71.9% for biochemotherapy,46.2% for biotherapy and 54.2% for chemotherapy(P
3.Clinical study of the treatment of advanced non small cell lung cancer in elderly over 70 years by gemcitabine
Liushu LI ; Ruliang WANG ; Hui ZHAO ; Jianhua ZHU ; Nan DU
Chinese Journal of Geriatrics 2001;0(01):-
Objective To evaluate the efficacy, toxicity and clinical benefit response of gemcitabine on advanced non small cell lung cancer in elderly. Methods Patients in the chemotherapy arm of the study received gemcitabine 1 250 mg/ m 2 as a intravenous infusion every 21 days .Patients in the best supportive care(BSC) arm should not receive chemotherapy or anticancer therapy. Results Overall survival period in the gemcitabine arm was significantly longer than in the BSC arm ( P